Literature DB >> 24872398

DHIM supporting immunologic investigations and the identification of immune correlates of protection.

Alan L Rothman1.   

Abstract

Evidence suggesting that immune responses to dengue virus (DENV) have the potential for both beneficial and detrimental effects on the outcome of infection is a concern for dengue vaccine development. There is thus a great need to define measures of DENV-specific immune responses that reliably indicate when immunity is protective. The existence of 4 main DENV serotypes and the difficulty in defining which individuals have been exposed and to which viruses present challenges to defining immune correlates of protective immunity against DENV in field efficacy studies; experimental infection studies in humans offer a pathway to address these challenges.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  dengue; immune correlate; protective immunity

Mesh:

Substances:

Year:  2014        PMID: 24872398      PMCID: PMC4036387          DOI: 10.1093/infdis/jiu111

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Memory CD8+ T cells in heterologous antiviral immunity and immunopathology in the lung.

Authors:  H D Chen; A E Fraire; I Joris; M A Brehm; R M Welsh; L K Selin
Journal:  Nat Immunol       Date:  2001-11       Impact factor: 25.606

Review 2.  Vaccines: correlates of vaccine-induced immunity.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

3.  A prospective study of dengue infections in Bangkok.

Authors:  D S Burke; A Nisalak; D E Johnson; R M Scott
Journal:  Am J Trop Med Hyg       Date:  1988-01       Impact factor: 2.345

4.  Risk factors in dengue shock syndrome.

Authors:  S Thein; M M Aung; T N Shwe; M Aye; A Zaw; K Aye; K M Aye; J Aaskov
Journal:  Am J Trop Med Hyg       Date:  1997-05       Impact factor: 2.345

Review 5.  Critical issues in dengue vaccine development.

Authors:  Stephen J Thomas; Timothy P Endy
Journal:  Curr Opin Infect Dis       Date:  2011-10       Impact factor: 4.915

6.  Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

Authors:  Timothy P Endy; Ananda Nisalak; Supamit Chunsuttitwat; David W Vaughn; Sharone Green; Francis A Ennis; Alan L Rothman; Daniel H Libraty
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

7.  PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE.

Authors:  A B Sabin; R W Schlesinger
Journal:  Science       Date:  1945-06-22       Impact factor: 47.728

Review 8.  Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes.

Authors:  Scott B Halstead; Suresh Mahalingam; Mary A Marovich; Sukathida Ubol; David M Mosser
Journal:  Lancet Infect Dis       Date:  2010-10       Impact factor: 25.071

9.  Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue.

Authors:  Stéphanie Devignot; Cédric Sapet; Veasna Duong; Aurélie Bergon; Pascal Rihet; Sivuth Ong; Patrich T Lorn; Norith Chroeung; Sina Ngeav; Hugues J Tolou; Philippe Buchy; Patricia Couissinier-Paris
Journal:  PLoS One       Date:  2010-07-20       Impact factor: 3.240

10.  Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion.

Authors:  S B Halstead
Journal:  Yale J Biol Med       Date:  1970-04
View more
  2 in total

1.  An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.

Authors:  Stefan Fernandez; Stephen J Thomas; Rafael De La Barrera; Rawiwan Im-Erbsin; Richard G Jarman; Benoît Baras; Jean-François Toussaint; Sally Mossman; Bruce L Innis; Alexander Schmidt; Marie-Pierre Malice; Pascale Festraets; Lucile Warter; J Robert Putnak; Kenneth H Eckels
Journal:  Am J Trop Med Hyg       Date:  2015-02-02       Impact factor: 2.345

2.  Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.

Authors:  Philippe Moris; Kristen M Bauer; Jeffrey R Currier; Heather Friberg; Kenneth H Eckels; Ines O Esquilin; Robert V Gibbons; Bruce L Innis; Richard G Jarman; Sriluck Simasathien; Peifang Sun; Stephen J Thomas; Veerachai Watanaveeradej
Journal:  Hum Vaccin Immunother       Date:  2019-04-15       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.